Market Overview

UPDATE: Wedbush Lowers Medifast's PT

Related MED
Benzinga's Top Upgrades, Downgrades For August 17, 2017
Earnings Scheduled For March 9, 2017

According to a research report published this morning, Wedbush has lowered Medifast's (NYSE: MED) PT from $23 to $22.

In the report, Wedbush commented, "Return to double-digit growth in direct-selling business leads to revenue upside. Q1 revenues of $89 million exceeded the consensus estimate of $87 million on 13% growth in Take Shape for Life, the direct-selling arm, to $53 million, due to a 2% increase in active health coaches and 3% increase in productivity."

Wedbush maintains its Outperform rating on Medifast, which is currently trading at $16.57.

Latest Ratings for MED

Sep 2017DA DavidsonMaintainsBuy
Aug 2017DA DavidsonInitiates Coverage OnBuy
Jan 2016WunderlichInitiates Coverage onHold

View More Analyst Ratings for MED
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings


Related Articles (MED)

View Comments and Join the Discussion!